Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
Michael Pan(University of Michigan), Tariq U. Azam(University of Michigan), Rodica Pop‐Busui(University of Michigan), Erinleigh Michaud(University of Michigan), Chelsea Meloche(University of Michigan), Patrick O’Hayer(University of Michigan), Élizabeth Anderson(Wellcome Sanger Institute), Hanna Berlin(University of Michigan), Pennelope Blakely(University of Michigan), Sven H. Loosen(RWTH Aachen University), Toniemarie Catalan(University of Michigan), Husam Shadid(University of Michigan), Jesper Eugen‐Olsen(Hvidovre Hospital), Alexi Vasbinder(University of Washington), Jochen Reiser(University of Miami), Athanasios Chalkias(University of Thessaly), Frank Tacke(Medizinische Hochschule Hannover), Salim S. Hayek(Emory University), Abbas Bitar(University of Michigan), Lili Zhao(University of Michigan), Yiyuan Huang(Affiliated Hospital of Youjiang Medical University for Nationalities), Ibrahim Khaleel(University of Michigan), Evangelos J. Giamarellos‐Bourboulis(National and Kapodistrian University of Athens), Kishan Padalia(University of Michigan)
Cited by 29
Related Papers
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
|Cell Host & Microbe|2020|2.3k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k